We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current IMUN market cap is 7.78M. The company's latest EPS is USD -0.0197 and P/E is -4.57.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.84M | -887k | -739k | -1.16M | -1.49M |
| Net Income | -3.4M | 1.59M | 3.59M | -3.54M | -1.65M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 6k | 10k | 3.14M | 964k | 743k |
| Total Liabilities | 13.69M | 11.68M | 11.09M | 3.48M | 4.56M |
| Total Equity | -13.69M | -11.67M | -7.95M | -2.51M | -3.82M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -1,000 | -192k | -232k | -582k | -657k |
| Investing | N/A | N/A | N/A | -500k | N/A |
| Financing | N/A | 197k | 716k | 738k | 536k |
| Market Cap | 7.78M |
| Price to Earnings Ratio | -4.57 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 225 |
| Price to Book Ratio | -1.97 |
| Dividend Yield | - |
| Shares Outstanding | 83.66M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -84.50% |
| 52 Week High | 0.90 |
| 52 Week Low | 0.06675 |
| Spread (Intraday) | 0.03 (28%) |
| Company Name | Immune Therapeutics Inc (PK) |
| Address |
37 north orange ave, suite 607 orlando, florida 32801 |
| Website | https://www.immunetherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
